On August 5, 2014, Neurotrope, Inc. announced the following receipt of a notice from Northlea Partners LLLP removing Dr. James New as one of Northlea's director designees pursuant to the Amended and Restated Stockholder Agreement dated August 23, 2013 among Neurotrope, Inc., Dr. New, Northlea, Dr. Dan Alkon, and Neuroscience Research Ventures, Inc., stockholders of the Company, representing not less than two-thirds of the
voting power of the issued and outstanding common stock entitled to vote, acted by written consent to remove James New from the Company's board of directors, effective as of August 5, 2014.